CCTG Clinical Trials
Public Trial Select
Member Trial Select
International research collaboration explores blood-based biomarkerUsing non-invasive approaches to confirm POLE and POLD1 mutations in solid tumors and to investigate whether those tumors are responsive to immunotherapy. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Landmark clinical trial reports 33% prostate cancer survival benefit from novel hormone therapy
Just presented at ASCO 2019 the landmark ENZAMET | CCTG PR17 (NCT02446405) clinical trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer. Findings, show that men with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in survival compared to men receiving standard treatment alone.
“The benefits of enzalutamide had already been established for prostate cancers that are no longer responding to hormonal therapy,” said ENZAMET study co-chair, Professor Ian Davis from the lead group the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). “The actual result in patients starting hormonal therapy noted that patients had a 60% improvement in the time it takes to detect the cancer growing again along with a 33% increase chance of survival was far higher than we expected.”
“This data represents an important advance in our knowledge of how to treat this stage of prostate cancer and we look forward to longer term follow-up data on survival and treatment side effects as well as quality of life,” says CCTG Senior Investigator Dr. Wendy Parulekar.
More >>
2019 New Investigator Clinical Trials Course
Mark your calendars for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.
More >>
Canadian Cancer Trials Group awarded $25 million in funding to support clinical trials
The Canadian Cancer Trials Group (CCTG) has been awarded more than 19 million USD over six years (approximately $25 million CAD) from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI).
More >>
2019 New Investigator Clinical Trials Course
Mark your calendars for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.
More >>
Canadian Cancer Trials Group awarded $25 million in funding to support clinical trials
The Canadian Cancer Trials Group (CCTG) has been awarded more than 19 million USD over six years (approximately $25 million CAD) from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI).
More >>
Strength in Numbers
Patients facing a cancer diagnosis invariably have many questions, but one tops the list – what is the best treatment? Answering that question is the compelling goal of medical research that is testing new treatments for similarly-diagnosed patients in carefully monitored and controlled ways.
More >>
Innovative study advances personalized medicine for prostate cancer patients
A new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.
More >>Planned trials
CRC9
Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca
Recently activated
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
More >>
Canadian Cancer Research Alliance announces award winners
Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer (Queen's University) will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham (Canadian Cancer Trials Group and Canadian Cancer Clinical Trials Network) will receive the Exceptional Leadership in Patient Involvement in Cancer award.
More >>Publications
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219 (ONLINE)
Lung Cancer , 2019
Melosky B;Bradbury P;Tu D;Florescu M;Reiman A;Nicholas G;Basappa N;Rothenstein J;Goffin JR;Laurie SA;Wheatley-Price P;Leighl N;Goss G;Reaume MN;Butts C;Murray N;Card C;Ko J;Blais N;Gray S;Lui H;Brown-Walker P;Kaurah P;Prentice LM;Seymour L;
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis
J Clin Oncol 37: 1102 - 1110, 2019
Litiere S;Isaac G;de Vries EGE;Bogaerts J;Chen A;Dancey J;Ford R;Gwyther S;Hoekstra O;Huang E;Lin N;Liu Y;Mandrekar S;Schwartz LH;Shankar L;Therasse P;Seymour L;
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC)
J Clin Oncol 37, 2019
Chen EX;Jonker DJ;Kennecke HF;Berry SR;Couture F;Ahmad CE;Goffin JR;Kavan P;Harb M;Colwell B;Samimi S;Samson B;Abbas T;Aucoin N;Aubin F;Koski SL;Wei AC;Magoski NM;Tu D;O'Callaghan CJ;
LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/ Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer
Clin Lung Cancer 20: 66 - 73, 2019
Seymour L;Le Teuff G;Brambilla E;Shepherd FA;Soria JC;Kratzke R;Graziano S;Douillard JY;Rosell R;Reiman A;Lacas B;Lueza B;viel-Ronen S;McLeer A;Le Chevalier T;Pirker R;Filipits M;Dunant A;Pignon JP;Tsao MS;
Outcomes of Older Patients(>= 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20
Clinical Colorectal Cancer 18: e140 - e149, 2019
Wells JC;Tu D;Siu LL;Shapiro JD;Jonker DJ;Karapetis CS;Simes J;Liu G;Price TJ;Tebbutt NC;O'Callaghan CJ;
Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes
Clinical Trials 16: 14 - 17, 2019
Hay AE;Pater JL;Corn E;Han L;Camacho X;O'Callaghan C;Chong N;Bell EN;Tu D;Earle CC;
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis (ONLINE)
Leuk Lymphoma : 1 - 8, 2019
Al-Mansour Z;Cook JR;Constine LS;Couban S;Stewart DA;Shea TC;Porcu P;Winter JN;Kahl BS;Smith SM;Marcellus DC;Barton KP;Mills GM;LeBlanc M;Rimsza LM;Forman SJ;Leonard JP;Fisher RI;Friedberg JW;Stiff PJ;
Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218
Pediatr Blood Cancer 66: e27540, 2019
Deyell RJ;Wu B;Rassekh SR;Tu D;Samson Y;Fleming A;Bouffet E;Sun X;Powers J;Seymour L;Baruchel S;Morgenstern DA;